Welcome to our dedicated page for Enzo Biochem news (Ticker: ENZ), a resource for investors and traders seeking the latest updates and insights on Enzo Biochem stock.
Enzo Biochem, Inc. (historically ENZ on the NYSE and later ENZB on OTCQX) generated a steady stream of corporate and financial news as a life sciences company focused on labeling and detection technologies from DNA to whole cell analysis. Its disclosures highlight a portfolio of thousands of products, including antibodies, genomic probes, assays, biochemicals, and proteins that support translational research and drug development in areas such as cell biology, genomics, immunohistochemistry, and small molecule chemistry.
The company’s news flow has included quarterly and annual financial results, where Enzo reported on revenue trends in its Life Sciences division, gross margin performance, operating loss or income, and the impact of cost containment initiatives and product mix. These releases often discussed demand from drug development and cell and gene therapy market segments, as well as the use of non-GAAP measures like Adjusted net loss and Adjusted EBITDA, with reconciliations provided in accompanying tables.
Enzo’s announcements have also covered strategic and corporate actions, such as its exit from the clinical lab business, focus on life science tools, workforce and cost initiatives, and product life cycle management, including removal of non-performing SKUs and new product launches. Governance and corporate updates have included officer appointments, board changes, and shareholder meeting results.
In 2025, the news record shows important capital markets and M&A developments, including NYSE non-compliance notices, a voluntary delisting from the NYSE, transfer of trading to OTCQX, and the subsequent agreement and completion of a merger with Bethpage Parent, Inc., after which Enzo became a wholly owned subsidiary and its shares ceased trading. For readers reviewing ENZ or ENZB news, this page serves as a historical archive of earnings releases, strategic reviews, listing changes, and merger-related communications.
Enzo Biochem, Inc. (NYSE:ENZ) has partnered with CPESN NY to provide COVID-19 testing at 52 independent pharmacies across New York. This initiative aims to enhance community access to testing, essential during the pandemic. The program leverages Enzo's AMPIPROBE® SARS-CoV-2 swab molecular test, known for its rapid results within two to three days. Enzo's extensive experience in diagnostics and support services bolsters this effort, offering reliable testing solutions to communities in need.
Enzo Biochem, Inc. (NYSE: ENZ) has received Emergency Use Authorization (EUA) from the FDA for its AMPIPROBE® SARS-CoV-2 Test System, allowing use on three platforms: its own GENFLEX™ platform, Qiagen’s QIAsymphony® SP, and a manual workflow. This authorization enables laboratories to utilize the test without additional validation. The AMPIPROBE® system includes components for sample collection, processing, and detection, aimed at addressing COVID-19 testing needs amidst supply limitations.
Enzo Biochem partners with Farmingdale State College to provide molecular and antibody testing for COVID-19 as the college reopens. This collaboration falls under Enzo's School and Institution Testing (SIT) Program, aiming to ensure safety and compliance for students and staff. Testing will be available to all campus members at no financial cost, leveraging Enzo's Long Island-based resources. The initiative includes onsite testing clinics and prioritizes immediate testing needs. Enzo aims to support educational institutions nationwide with similar COVID-19 testing solutions.
Enzo Biochem reported third quarter revenues of $16.9 million, a 14% decline from last year, primarily due to COVID-19 impacts. The company faced a net loss of ($9.9) million or ($0.21 per share). Clinical Services revenue decreased to $10.5 million, driven by a 28% reduction in accession volume. Despite challenges, Enzo launched an extensive COVID-19 program and saw improvements in clinical services gross margins, now at 12.9%. Cash and equivalents reached $55 million, indicating proactive financial management amid ongoing challenges.
Enzo Biochem, Inc. (NYSE: ENZ) will announce its third quarter 2020 financial results on June 8, 2020, after market close. Following the release, President Barry Weiner and CFO David Bench will host a conference call at 5:00 PM ET to discuss the financial results and address investor questions. The call will be accessible via an audio webcast.